A spatial immune scoring system based on the tumor microenvironment features improves prognostic stratification in lung adenocarcinoma.

Wei Luo¹, Jia Jia², Qi Wang¹, Xiaoqing Li¹, Fang Yang³, Yongtian Zhao⁴, Zilu Li⁵, Lin Li⁶, Xiaodan Wang⁶, Mingyao Meng⁶, Haiyan Guo⁶, Wanli Zheng⁷, Liqiong Wang³, Dingbiao Li⁸, Zongliu Hou⁹, Yangfan Guo¹⁰

¹Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Precision Medicine Center, Kunming, China.

²Fujungenetics Biotechnology Co., Ltd, Shanghai, China.

³Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Department of Pathology, Kunming, China.

⁴Indica Labs, Inc, Albuquerque, United States.

⁵Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Xinjiang University of Technology, School of Big Data and Information Engineering, Hotan, China.

⁶Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China.

⁷Chinese Peoples Armed Police Force, Yunnan Prov Corps Hosp, Kunming, Inpatient Dept, China.

⁸Yan'an Hospital Affiliated To Kunming Medical University, Department of Thoracic Surgery, Kunming, China.

⁹Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yunnan Key Laboratory of Tumor Immunological Prevention and Control, Kunming, China. Electronic address: hzl579@163.com.

¹⁰Yan'an Hospital Affiliated To Kunming Medical University, Central Laboratory, Kunming, China; Yan'an Hospital Affiliated To Kunming Medical University, Precision Medicine Center, Kunming, China. Electronic address: guoyangfan@kmmu.edu.cn.

PubMed PMC DOI PDF

Abstract

The spatial heterogeneity of the tumor immune microenvironment (TME) in lung adenocarcinoma (LUAD) limits the prognostic accuracy of traditional TNM staging. Moreover, conventional T cell based immune scores established for other solid tumors fail to effectively stratify patient outcomes in LUAD. To address this, we applied quantitative multiplex immunofluorescence to map the spatial immune contex…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.